General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. Pharmacy benefit manager reform proposals.
2025 · 1st Quarter (Jan 1 - Mar 31)
AMGEN, INC.
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- AMGEN, INC.
- Filing UUID
- 6c29cf30-3e16-40c6-934c-cb29556f49cc
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Pharmacy benefit manager reform proposals.
Tax issues related to the pharmaceutical industry.
Policies impacting disease prevention.
Issues related to antitrust legislation
Issues related to patent protections.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.